Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: Its association with DNA methylation alteration and patient outcome

Clinical Cancer Research

Volumn 14, Issue 17, 2008, Pages 5531-5539

  Arai, Eri ^a   Ushijima, Saori ^a   Tsuda, Hitoshi ^b   Fujimoto, Hiroyuki ^a   Hosoda, Fumie ^a   Shibata, Tatsuhiro ^a   Kondo, Tadashi ^a   Imoto, Issei ^a   Inazawa, Johji ^a   Hirohashi, Setsuo ^a   Kanai, Yae ^a,c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; PROTEIN MINT 1; PROTEIN MINT 12; PROTEIN MINT 2; PROTEIN MINT 25; PROTEIN MINT 31; PROTEIN MUTL; PROTEIN P16; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; HOMEODOMAIN PROTEIN; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SPEN PROTEIN, HUMAN; THROMBOSPONDIN;

ADULT; AGED; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME 13Q; CHROMOSOME 14Q; CHROMOSOME 1P; CHROMOSOME 3P; CHROMOSOME 4; CHROMOSOME 5Q; CHROMOSOME 7; CHROMOSOME 9; CHROMOSOME LOSS; CLEAR CELL CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE CLUSTER; GENE MUTATION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY VEIN THROMBOSIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; PRIORITY JOURNAL; CHROMOSOME DELETION; CLUSTER ANALYSIS; CPG ISLAND; DNA MICROARRAY; GENE DOSAGE; GENETICS; KIDNEY TUMOR; MORTALITY; MUTATION; NUCLEIC ACID HYBRIDIZATION; PROGNOSIS; TUMOR SUPPRESSOR GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOMA, RENAL CELL; CHROMOSOME DELETION; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CLUSTER ANALYSIS; CPG ISLANDS; DNA METHYLATION; GENE DOSAGE; GENES, P16; HOMEODOMAIN PROTEINS; HUMANS; KIDNEY NEOPLASMS; MUTATION; NUCLEAR PROTEINS; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; THROMBOSPONDINS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 53049094107     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0443     Document Type: Article

References (32)

1. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization classification of tumours. Pathologyandgenetics.Tumours of theurinary system and male genital organs. Lyon: IARC Press; 2004. pp.10-43.
2. Jones J, Libermann TA. Genomics of renal cell cancer: the biology behind and the therapy ahead. Clin Cancer Res 2007;13:685-92s.
3. Guida M, Colucci G. Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet? Ann Oncol 2007;18:149 -52.
4. Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006;12:7215-20.
5. Kondo K,Yao M,Yoshida M, et al. Comprehensive mutational analysis of the VHL geneinsporadicrenal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002;34:58-68.
6. Wilhelm M,Veltman JA, Olshen AB, et al. Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res 2002;62:957 -60.
7. Yoshimoto T, Matsuura K, Karnan S, et al. High- resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma. J Pathol 2007;213:392 -401.
8. Arai E, Kanai Y, Ushijima S, Fujimoto H, Mukai K, Hirohashi S. Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpressionin both renal tumorsand correspondi ngnontumorousrenal tissues. Int J Cancer 2006;119:288-96.
9. Kanai Y, Hirohashi S. Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis 2007; 28:2434-42.
10. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA1999; 96:8681 -6.
11. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655 -63.
12. Sobin LH,Wittekind Ch. International Union Against Cancer (UICC). TNM classification of malignant tumors, 6th ed. NewYork: Wiley-Liss; 2002. p. 193-5.
13. Inazawa J, Inoue J, Imoto I. Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes. Cancer Sci 2004;95:559-63.
14. Sonoda I, Imoto I, Inoue J, et al. Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression bygenetic and epigenetic mechanismsin esophageal squamous cell carcinoma. Cancer Res 2004;64:3741 -7.
15. Shibata T, Uryu S, Kokubu A, et al. Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. Clin Cancer Res 2005;11:6177-85.
16. Tsuda H. HER-2 (c-erbB-2) testupdate: presentstatus and problems. Breast Cancer 2006;13:236 -48.
17. Kanai Y, Ushijima S, KondoY, Nakanishi Y, Hirohashi S. DNA methyltransferase expression and DNAmeth- ylation of CpG islands and peri-centromeric satellite regions in human colorectal and stomach cancers. Int J Cancer 2001;91:205-12.
18. Etoh T, Kanai Y, Ushijima S, et al. Increased DNA methyltransferase1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol 2004;164:689-99.
19. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821 -6.
20. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998;95:6870-5.
21. Yokoo H, Kondo T, Fujii K, Yamada T, Todo S, Hirohashi S. Proteomic signature corresponding to a fetoprotein expression in liver cancer cells. Hepatology 2004;40:609 -17.
22. Seike M, Kondo T, Fujii K, et al.Proteomic signature of human cancer cells. Proteomics 2004;4:2776 -88.
23. Junker K, Weirich G, Amin MB, Moravek P, Hindermann W, Schubert J. Genetic subtyping of renal cell carcinoma by comparative genomic hybridization. Recent Results Cancer Res 2003;162:169 -75.
24. Alimov A, Sundelin B, Bergerheim U, et al. Molecular cytogenetic characterization shows higher genetic homogeneity in conventional renal cell carcinoma compared to other kidney cancers. Int J Oncol 2004; 25:955-60.
25. Sanjmyatav J, Schubert J, Junker K. Comparative study of renal cell carcinoma by CGH, multicolor-FISH and conventional cytogenic banding analysis. Oncol Rep 2005;14:1183-7.
26. Receveur AO, Couturier J, Molinie V, et al. Characterization of quantitative chromosomal abnormalities in renal cell carcinomas by interphase four-color fluorescence in situ hybridization. Cancer Genet Cytogenet 2005;158:110-8.
27. Barocas DA, Mathew S, DelPizzo JJ, et al. Renal cell carcinoma sub-typing by histopathology and fluorescence in situ hybridization on a needle-biopsy specimen. BJU Int 2007;99:290-5.
28. Bonsib SM. T2 clear cell renal cell carcinoma is a rare entity: a study of 120 clear cell renal cell carcinomas. J Urol 2005;174:1199 -202.
29. Brunelli M, Eccher A, Gobbo S, et al. Loss of chromo- some 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. Mod Pathol 2008;21:1 -6.
30. Presti JC, Jr., Wilhelm M, Reuter V, Russo P, Motzer R, Waldman F. Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. J Urol 2002;167:1464-8.
31. Kaku H, Ito S, Ebara S, et al. Positive correlation between allelic loss at chromosome14q24-31 and poor prognosis of patients with renal cell carcinoma. Urology 2004;64:176 -81.
32. Feuk L, Carson AR, Scherer SW. Structural variation in the human genome. Nat Rev Genet 2006;7:85-97.